Cell Line Development Market Research Based on Synthesis and Analysis on Techniques and Medical Applications Report 2020-2026
Cell line is a permanently established cell culture, which proliferates indefinitely if it is given appropriate fresh medium and space. Cell line is typically used to examine effectiveness of drug discovery and toxicity. Cell lines are crucial in the production of recombinant proteins production such as, monoclonal antibodies, bi-specific monoclonal antibodies, growth factors, and enzymes using a wide variety of expression systems. Cell lines saves the crucial time, effort and cost by providing the high yield cells, which can be used for in vitro testing and reduce chance of research drug to fail in clinical trial stage.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/1286
Market Dynamics- Drivers
Development of novel therapy to drive growth of the global cell line development market
Cell line development finds applications in various sectors including treatment of cancer. According to the World Health Organization (WHO) factsheet 2012, cancer is one of the leading cause of death from top three causes of non-communicable disease. Pharmaceutical and biotechnological companies are involved in development of novel therapies such as immunotherapy, owing to its specificity and efficiency. Cell line development is extremely useful in speeding drug discovery process and optimization of clinical trials by providing high yield of monoclonal antibodies, which is expected to drive growth of the global cell line development market during the forecast period.
Moreover, introduction of novel technologies in cell line development are expected to drive growth of the global cell line development market in the near future. For instance, in November 2017, Lonza group launched Multiplex Cell line culture using GS Xceed Gene Expression System., which helps in testing multiple drug candidate at early developmental stage thereby saving four to six months, which otherwise is required in conventional development program.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1286
Global Cell Line Development Market Taxonomy
On the basis of product type:
- Reagents & Media
On the basis of source:
On the basis of cell line:
- Continuous Cell Line
- Primary Cell Line
On the basis of application:
- Drug Discovery
- Toxicity Testing
- Tissue Engineering
On the basis of end-user:
- Pharmaceutical companies
- Research and Academic Institution
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/cell-line-development-market-1286
North America to hold dominant position in the global cell line development market, owing to high investment in research by pharmaceutical companies to develop novel product
Among regions, North America is expected to hold dominant position in the global cell line development market in the near future. This is owing to significant investment by pharmaceutical companies to develop novel treatment products coupled with increasing off-patenting of major products that would promote biosimilar drug development. Biosimilar drugs having biological molecule needs to match in structure and composition with original product which needs cell line to confirm matching of structure and adhere to quality attribute such as glycoprofile, protein aggregation. For instance, according to 2016 report of International Trade Administration of Department of Commerce (USA), the U.S. generic drug sales reached an estimated US$ 70 billion in 2015, which represents quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favoring generics development. According to the same report, biologics account for over a third of all new drugs in clinical trials or which are waiting for the U.S. Food and Drug Administration approval. According to Pharmaceutical Research and Manufacturers of America, companies such as Novartis AG, Merck and Company and F. Hoffmann-LA Roche AG in U.S. together invested in US$ 75 billion in research and development. Legal factors such Affordable Care Act, which has already covered the most of population is expected to boost the usage for novel products as patients can get treated with insurance coverage without out of pocket expenditure on such medication.
Collaborations by cell line development companies with drug discovery companies to speed up expansion of the global cell line development market
Key companies operating in the global cell line development market include Lonza Group AG, Sigma-Aldrich Corporation, Wuxi App Tec, Inc., American Type Culture Collection, Thermo Fisher Scientific, Inc., PX’Therapeutics SA., Selexis SA, GE Healthcare, European Collection of Cell Cultures, Corning, Inc., Sartorious AG, Goodwin Biotechnology Inc., and Cleancells.
- In December 2017, Selexis SA entered into third commercial license agreement with Turgut Pharmaceuticals, which would provide Turgut with access to Selexis SUREtechnology Platform and SURE CHO-M Cell Line for the development of biosimilar product for the treatment of two rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The companies were already in agreement (made in July 2016) to develop biosimilar products to treat inflammatory diseases and certain cancers using the SURE CHO-M Cell Lines.
- In October 2017, Selexis SA entered into an agreement with Pelican Therapeutics (subsidiary of Heat Biologics, Inc.) for the development of Pelican’s immunotherapy clinical candidates PTX-35 and PTX-15. Pelican would utilize Selexis’s SUREtechnology PlatformTM to rapidly develop high-performance research cell banks expressing two of research candidate such as PTX-35, which is humanized monoclonal antibody that is a functional agonist of human TNFRSF25, and PTX-15, which is a human TL1A-Ig fusion protein.
- In November 2017, American Type Culture Collection introduced an innovative in vitro model system of cell lines for key mechanism of invasion and metastasis in lung cancer
- In January 2018, PX’Therapeutics collaborated with biotech firm Advaxis for process development of immunotherapies of Advaxis
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire